Overview JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis Status: Recruiting Trial end date: 2022-10-31 Target enrollment: Participant gender: Summary To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis Phase: Phase 3 Details Lead Sponsor: Onconic Therapeutics Inc.